FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CytoDyn's Free Cash Flow for the
three
months ended in Feb. 2024 was $-2.34 Mil. CytoDyn's Revenue for the
three
months ended in Feb. 2024 was $0.00 Mil. Therefore, CytoDyn's FCF Margin % for the quarter that ended in Feb. 2024 was 0.00%.
As of today, CytoDyn's current FCF Yield % is -8.64%.
The historical rank and industry rank for CytoDyn's FCF Margin % or its related term are showing as below:
During the past 13 years, the highest FCF Margin % of CytoDyn was -29219.17%. The lowest was -29219.17%. And the median was -29219.17%.
CYDY's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -148.24 * Ranked among companies with meaningful FCF Margin % only.
CytoDyn FCF Margin % Historical Data
The historical data trend for CytoDyn's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CytoDyn's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoDyn's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoDyn's FCF Margin % distribution charts can be found below:
* The bar in red indicates where CytoDyn's FCF Margin % falls into.
CytoDyn FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
CytoDyn's FCF Margin for the fiscal year that ended in May. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoDyn FCF Margin % Related Terms
Thank you for viewing the detailed overview of CytoDyn's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoDyn Inc is a US-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CYDY has been successfully added to your 